Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 4/2004

01-04-2004 | Original Article

Dendritic cells loaded with exogenous antigen by electroporation can enhance MHC class I–mediated antitumor immunity

Authors: Kwang-Woon Kim, Sun-Hee Kim, Jung-Hee Jang, Eun-Yup Lee, Soon-Won Park, Jee-Hyun Um, Yun-Jung Lee, Chang-Hun Lee, Sik Yoon, Su-Yeong Seo, Min-Ho Jeong, Seong-Tae Lee, Byung-Seon Chung, Chi-Dug Kang

Published in: Cancer Immunology, Immunotherapy | Issue 4/2004

Login to get access

Abstract

To develop an efficient antitumor immunotherapy, we have examined if dendritic cells (DCs) loaded with soluble antigens by electroporation present more antigens via the MHC (major histocompatibility complex) class I pathway, which mediate a cytotoxic T-cell response. DCs loaded with ovalbumin (OVA) by electroporation presented more MHC class I–restricted determinants compared with DCs pulsed with OVA. When electroporated DCs were pulsed with OVA for additional times, both MHC class I– and II–restricted presentation of OVA were increased compared with each single procedure, including electroporation or simple pulse. Immunization with DCs loaded with OVA by electroporation induced higher cytotoxicity of splenocytes to E.G7 cells, a clone of EL4 cells transfected with an OVA cDNA, than immunization with DCs pulsed with OVA. In the animal study, immunization with DCs loaded with OVA or tumor cell lysates by electroporation induced an effective antitumor immunity against tumor of E.G7 cells or Lewis lung carcinoma cells, respectively. In addition, immunization with DCs loaded with antigen by combination of electroporation and pulse, completely protected mice from tumor formation, and prolonged survival, in both tumor models. These results demonstrated that electroporation would be a useful way to enhance MHC class I–mediated antitumor immunity without functional deterioration, and that the combination of electroporation and pulse could be a simple and efficient antigen-loading method and consequently lead to induction of strong antitumor immunity.
Literature
1.
go back to reference Bachmann MF, Lutz MB, Layton GT, Harris SJ, Fehr T, Rescigno M, Ricciardi-Castagnoli P (1996) Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+ cytotoxic T lymphocytes. Eur J Immunol 26:2595PubMed Bachmann MF, Lutz MB, Layton GT, Harris SJ, Fehr T, Rescigno M, Ricciardi-Castagnoli P (1996) Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+ cytotoxic T lymphocytes. Eur J Immunol 26:2595PubMed
2.
go back to reference Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K (2000) Immunobiology of dendritic cells. Annu Rev Immunol 18:767PubMed Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K (2000) Immunobiology of dendritic cells. Annu Rev Immunol 18:767PubMed
3.
go back to reference Brossart P, Wirths S, Brugger W, Kanz L (2001) Dendritic cells in cancer vaccines. Exp Hematol 29:1247CrossRefPubMed Brossart P, Wirths S, Brugger W, Kanz L (2001) Dendritic cells in cancer vaccines. Exp Hematol 29:1247CrossRefPubMed
4.
go back to reference Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD Jr (1996) Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 183:283PubMed Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD Jr (1996) Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 183:283PubMed
5.
go back to reference De Veerman M, Heirman C, Van Meirvenne S, Devos S, Corthals J, Moser M, Thielemans K (1999) Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity. J Immunol 162:144PubMed De Veerman M, Heirman C, Van Meirvenne S, Devos S, Corthals J, Moser M, Thielemans K (1999) Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity. J Immunol 162:144PubMed
6.
go back to reference Delamarre L, Holcombe H, Mellman I (2003) Presentation of exogenous antigens on major histocompatibility complex (MHC) class I and MHC class II molecules is differentially regulated during dendritic cell maturation. J Exp Med 198:111CrossRefPubMed Delamarre L, Holcombe H, Mellman I (2003) Presentation of exogenous antigens on major histocompatibility complex (MHC) class I and MHC class II molecules is differentially regulated during dendritic cell maturation. J Exp Med 198:111CrossRefPubMed
7.
go back to reference Fanger NA, Wardwell K, Shen L, Tedder TF, Guyre PM (1996) Type I (CD64) and type II (CD32) Fc gamma receptor-mediated phagocytosis by human blood dendritic cells. J Immunol 157:541PubMed Fanger NA, Wardwell K, Shen L, Tedder TF, Guyre PM (1996) Type I (CD64) and type II (CD32) Fc gamma receptor-mediated phagocytosis by human blood dendritic cells. J Immunol 157:541PubMed
8.
go back to reference Fanger NA, Voigtlaender D, Liu C, Swink S, Wardwell K, Fisher J, Graziano RF, Pfefferkorn LC, Guyre PM (1997) Characterization of expression, cytokine regulation, and effector function of the high affinity IgG receptor Fc gamma RI (CD64) expressed on human blood dendritic cells. J Immunol 158:3090PubMed Fanger NA, Voigtlaender D, Liu C, Swink S, Wardwell K, Fisher J, Graziano RF, Pfefferkorn LC, Guyre PM (1997) Characterization of expression, cytokine regulation, and effector function of the high affinity IgG receptor Fc gamma RI (CD64) expressed on human blood dendritic cells. J Immunol 158:3090PubMed
9.
go back to reference Fields RC, Shimizu K, Mule JJ (1998) Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci U S A 95:9482CrossRefPubMed Fields RC, Shimizu K, Mule JJ (1998) Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci U S A 95:9482CrossRefPubMed
10.
go back to reference Flamand V, Sornasse T, Thielemans K, Demanet C, Bakkus M, Bazin H, Tielemans F, Leo O, Urbain J, Moser M (1994) Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol 24:605PubMed Flamand V, Sornasse T, Thielemans K, Demanet C, Bakkus M, Bazin H, Tielemans F, Leo O, Urbain J, Moser M (1994) Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol 24:605PubMed
11.
go back to reference Fong L, Engleman EG (2000) Dendritic cells in cancer immunotherapy. Annu Rev Immunol 18:245PubMed Fong L, Engleman EG (2000) Dendritic cells in cancer immunotherapy. Annu Rev Immunol 18:245PubMed
12.
go back to reference Gehl J (2003) Electroporation: theory and methods, perspectives for drug delivery, gene therapy and research. Acta Physiol Scand 177:437PubMed Gehl J (2003) Electroporation: theory and methods, perspectives for drug delivery, gene therapy and research. Acta Physiol Scand 177:437PubMed
13.
go back to reference Hui SW (2002) The application of electroporation to transfect hematopoietic cells and to deliver drugs and vaccines transcutaneously for cancer treatment. Technol Cancer Res Treat 1:373PubMed Hui SW (2002) The application of electroporation to transfect hematopoietic cells and to deliver drugs and vaccines transcutaneously for cancer treatment. Technol Cancer Res Treat 1:373PubMed
14.
go back to reference Hurwitz AA, Kwon ED, van Elsas A (2000) Costimulatory wars: the tumor menace. Curr Opin Immunol 12:589CrossRefPubMed Hurwitz AA, Kwon ED, van Elsas A (2000) Costimulatory wars: the tumor menace. Curr Opin Immunol 12:589CrossRefPubMed
16.
go back to reference Lambert H, Pankov R, Gauthier J, Hancock R (1990) Electroporation-mediated uptake of proteins into mammalian cells. Biochem Cell Biol 68:729PubMed Lambert H, Pankov R, Gauthier J, Hancock R (1990) Electroporation-mediated uptake of proteins into mammalian cells. Biochem Cell Biol 68:729PubMed
17.
go back to reference Lambert LA, Gibson GR, Maloney M, Barth RJ Jr (2001) Equipotent generation of protective antitumor immunity by various methods of dendritic cell loading with whole cell tumor antigens. J Immunother 24:232CrossRef Lambert LA, Gibson GR, Maloney M, Barth RJ Jr (2001) Equipotent generation of protective antitumor immunity by various methods of dendritic cell loading with whole cell tumor antigens. J Immunother 24:232CrossRef
18.
go back to reference Li Y, Ke Y, Gottlieb PD, Kapp JA (1994) Delivery of exogenous antigen into the major histocompatibility complex class I and class II pathways by electroporation. J Leukoc Biol 56:616PubMed Li Y, Ke Y, Gottlieb PD, Kapp JA (1994) Delivery of exogenous antigen into the major histocompatibility complex class I and class II pathways by electroporation. J Leukoc Biol 56:616PubMed
19.
go back to reference Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB et al (1995) Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1:1297PubMed Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB et al (1995) Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1:1297PubMed
20.
go back to reference McIlroy D, Gregoire M (2003) Optimizing dendritic cell–based anticancer immunotherapy: maturation state does have clinical impact. Cancer Immunol Immunother (in press) McIlroy D, Gregoire M (2003) Optimizing dendritic cell–based anticancer immunotherapy: maturation state does have clinical impact. Cancer Immunol Immunother (in press)
21.
go back to reference Mir LM, Banoun H, Paoletti C (1988) Introduction of definite amounts of nonpermeant molecules into living cells after electropermeabilization: direct access to the cytosol. Exp Cell Res 175:15PubMed Mir LM, Banoun H, Paoletti C (1988) Introduction of definite amounts of nonpermeant molecules into living cells after electropermeabilization: direct access to the cytosol. Exp Cell Res 175:15PubMed
22.
go back to reference Nestle FO (2000) Dendritic cell vaccination for cancer therapy. Oncogene 19:6673PubMed Nestle FO (2000) Dendritic cell vaccination for cancer therapy. Oncogene 19:6673PubMed
23.
go back to reference Norbury CC, Chambers BJ, Prescott AR, Ljunggren HG, Watts C (1997) Constitutive macropinocytosis allows TAP-dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow-derived dendritic cells. Eur J Immunol 27:280PubMed Norbury CC, Chambers BJ, Prescott AR, Ljunggren HG, Watts C (1997) Constitutive macropinocytosis allows TAP-dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow-derived dendritic cells. Eur J Immunol 27:280PubMed
24.
go back to reference Nouri-Shirazi M, Banchereau J, Fay J, Palucka K (2000) Dendritic cell based tumor vaccines. Immunol Lett 74:5PubMed Nouri-Shirazi M, Banchereau J, Fay J, Palucka K (2000) Dendritic cell based tumor vaccines. Immunol Lett 74:5PubMed
25.
go back to reference O’Reilly MS, Holmgren L, Chen C, Folkman J (1996) Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2:689PubMed O’Reilly MS, Holmgren L, Chen C, Folkman J (1996) Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2:689PubMed
26.
go back to reference Paglia P, Chiodoni C, Rodolfo M, Colombo MP (1996) Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 183:317PubMed Paglia P, Chiodoni C, Rodolfo M, Colombo MP (1996) Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 183:317PubMed
27.
go back to reference Porgador A, Snyder D, Gilboa E (1996) Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol 156:2918PubMed Porgador A, Snyder D, Gilboa E (1996) Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol 156:2918PubMed
28.
go back to reference Regnault A, Lankar D, Lacabanne V, Rodriguez A, Thery C, Rescigno M, Saito T, Verbeek S, Bonnerot C, Ricciardi-Castagnoli P, Amigorena S (1999) Fc gamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med 189:371CrossRefPubMed Regnault A, Lankar D, Lacabanne V, Rodriguez A, Thery C, Rescigno M, Saito T, Verbeek S, Bonnerot C, Ricciardi-Castagnoli P, Amigorena S (1999) Fc gamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med 189:371CrossRefPubMed
29.
go back to reference Reid DC (2001) Dendritic cells and immunotherapy for malignant disease. Br J Haematol 112:874PubMed Reid DC (2001) Dendritic cells and immunotherapy for malignant disease. Br J Haematol 112:874PubMed
30.
go back to reference Reinhard G, Marten A, Kiske SM, Feil F, Bieber T, Schmidt-Wolf IG (2002) Generation of dendritic cell-based vaccines for cancer therapy. Br J Cancer 86:1529CrossRefPubMed Reinhard G, Marten A, Kiske SM, Feil F, Bieber T, Schmidt-Wolf IG (2002) Generation of dendritic cell-based vaccines for cancer therapy. Br J Cancer 86:1529CrossRefPubMed
31.
go back to reference Renkvist N, Castelli C, Robbins PF, Parmiani G (2001) A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 50:3PubMed Renkvist N, Castelli C, Robbins PF, Parmiani G (2001) A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 50:3PubMed
32.
go back to reference Rescigno M, Citterio S, Thery C, Rittig M, Medaglini D, Pozzi G, Amigorena S, Ricciardi-Castagnoli P (1998) Bacteria-induced neo-biosynthesis, stabilization, and surface expression of functional class I molecules in mouse dendritic cells. Proc Natl Acad Sci U S A 95:5229CrossRefPubMed Rescigno M, Citterio S, Thery C, Rittig M, Medaglini D, Pozzi G, Amigorena S, Ricciardi-Castagnoli P (1998) Bacteria-induced neo-biosynthesis, stabilization, and surface expression of functional class I molecules in mouse dendritic cells. Proc Natl Acad Sci U S A 95:5229CrossRefPubMed
33.
go back to reference Rock KL, Benacerraf B (1983) Inhibition of antigen-specific T lymphocyte activation by structurally related Ir gene-controlled polymers: evidence of specific competition for accessory cell antigen presentation. J Exp Med 157:1618PubMed Rock KL, Benacerraf B (1983) Inhibition of antigen-specific T lymphocyte activation by structurally related Ir gene-controlled polymers: evidence of specific competition for accessory cell antigen presentation. J Exp Med 157:1618PubMed
34.
go back to reference Rock KL, Rothstein L, Gamble S (1990) Generation of class I MHC-restricted T-T hybridomas. J Immunol 145:804PubMed Rock KL, Rothstein L, Gamble S (1990) Generation of class I MHC-restricted T-T hybridomas. J Immunol 145:804PubMed
35.
go back to reference Rodriguez A, Regnault A, Kleijmeer M, Ricciardi-Castagnoli P, Amigorena S (1999) Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol 1:362CrossRefPubMed Rodriguez A, Regnault A, Kleijmeer M, Ricciardi-Castagnoli P, Amigorena S (1999) Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol 1:362CrossRefPubMed
36.
go back to reference Rosenberg SA (1999) A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10:281PubMed Rosenberg SA (1999) A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10:281PubMed
37.
go back to reference Rovere P, Vallinoto C, Bondanza A, Crosti MC, Rescigno M, Ricciardi-Castagnoli P, Rugarli C, Manfredi AA (1998) Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function. J Immunol 161:4467PubMed Rovere P, Vallinoto C, Bondanza A, Crosti MC, Rescigno M, Ricciardi-Castagnoli P, Rugarli C, Manfredi AA (1998) Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function. J Immunol 161:4467PubMed
38.
go back to reference Sallusto F, Cella M, Danieli C, Lanzavecchia A (1995) Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products [see comments]. J Exp Med 182:389PubMed Sallusto F, Cella M, Danieli C, Lanzavecchia A (1995) Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products [see comments]. J Exp Med 182:389PubMed
39.
go back to reference Specht JM, Wang G, Do MT, Lam JS, Royal RE, Reeves ME, Rosenberg SA, Hwu P (1997) Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J Exp Med 186:1213PubMed Specht JM, Wang G, Do MT, Lam JS, Royal RE, Reeves ME, Rosenberg SA, Hwu P (1997) Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J Exp Med 186:1213PubMed
40.
go back to reference Tarte K, Klein B (1999) Dendritic cell-based vaccine: a promising approach for cancer immunotherapy. Leukemia 13:653PubMed Tarte K, Klein B (1999) Dendritic cell-based vaccine: a promising approach for cancer immunotherapy. Leukemia 13:653PubMed
41.
go back to reference Thery C, Amigorena S (2001) The cell biology of antigen presentation in dendritic cells. Curr Opin Immunol 13:45CrossRefPubMed Thery C, Amigorena S (2001) The cell biology of antigen presentation in dendritic cells. Curr Opin Immunol 13:45CrossRefPubMed
42.
go back to reference White J, Haskins KM, Marrack P, Kappler J (1983) Use of I region-restricted, antigen-specific T cell hybridomas to produce idiotypically specific anti-receptor antibodies. J Immunol 130:1033PubMed White J, Haskins KM, Marrack P, Kappler J (1983) Use of I region-restricted, antigen-specific T cell hybridomas to produce idiotypically specific anti-receptor antibodies. J Immunol 130:1033PubMed
43.
go back to reference Yewdell JW, Norbury CC, Bennink JR (1999) Mechanisms of exogenous antigen presentation by MHC class I molecules in vitro and in vivo: implications for generating CD8+ T cell responses to infectious agents, tumors, transplants, and vaccines. Adv Immunol 73:1PubMed Yewdell JW, Norbury CC, Bennink JR (1999) Mechanisms of exogenous antigen presentation by MHC class I molecules in vitro and in vivo: implications for generating CD8+ T cell responses to infectious agents, tumors, transplants, and vaccines. Adv Immunol 73:1PubMed
44.
go back to reference Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ (1996) Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 183:87PubMed Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ (1996) Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 183:87PubMed
Metadata
Title
Dendritic cells loaded with exogenous antigen by electroporation can enhance MHC class I–mediated antitumor immunity
Authors
Kwang-Woon Kim
Sun-Hee Kim
Jung-Hee Jang
Eun-Yup Lee
Soon-Won Park
Jee-Hyun Um
Yun-Jung Lee
Chang-Hun Lee
Sik Yoon
Su-Yeong Seo
Min-Ho Jeong
Seong-Tae Lee
Byung-Seon Chung
Chi-Dug Kang
Publication date
01-04-2004
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 4/2004
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-003-0448-x

Other articles of this Issue 4/2004

Cancer Immunology, Immunotherapy 4/2004 Go to the issue

Acknowledgement to Reviewers

Acknowledgement to Reviewers in 2003

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine